Episode 870: What Sets Theralase Technologies’ ($TLT.V | $TLTFF) Ruvidar Apart in Bladder Cancer Treatment
This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies Inc. (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger Dumoulin-White, B.Sc, P. Eng. discusses the company’s clinical-stage cancer treatment technology and its development for patients with BCG-unresponsive non-muscle invasive bladder cancer. The interview covers interim Phase II clinical study results for Ruvidar®, including response durability and safety, as well as the potential advantages of Theralase’s drug and proprietary light activation system.Learn more: https://theralase.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=sb-_w3PoR_kAnd follow us to stay updated: https://www.youtube.com/@stockstowatchofficial
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Stocks To Watch
Episode 876: Sonoro Gold ($SGO | $SMOFF): Expanding Cerro Caliche Through District-Scale Exploration
Episode 875: Eastport Critical Metals ($EVI | $EVIIF): 330m Mineralized Intercept at Botswana Rare Earth Project
Episode 874: Eastport Critical Metals ($EVI | $EVIIF): Drilling for Copper, Uranium, REEs & Nickel in Botswana
Episode 873: $BRS Resources: Consistent Copper, Gold, & Silver Results Set the Stage for Maiden Drilling
Get summaries like this every morning.
Free AI-powered recaps of Stocks To Watch and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.